Newsletter Signup - Under Article / In Page
"*" indicates required fields
InSitu Biologics, Inc. has entered into an agreement with the Mayo Foundation for Medical Education and Research to further develop its prolonged-release drug delivery technology for anti-cancer therapeutics.
The company has developed an industry-leading platform technology for loading large doses of a variety of medications into a localized delivery matrix. Once injected, medication elutes from the multi-phase matrix over an extended period. The collaboration with Mayo is both a research and commercial endeavor, and will accelerate InSitu Biologics’ work in adapting the technology for anti-cancer therapeutics. The partnership will encompass traditional cancer medications as well as newly-developed novel agents.
“We are extremely excited to begin work with this group of amazing physicians and scientists. Their cutting-edge expertise and deep clinical experience will be invaluable as we extend our platform to address significant unmet needs in controlled-release drug delivery for cancer patients,” said Kevin Bassett, CEO of InSitu Biologics.
Inspiring hope
“Combining Mayo’s world-class expertise with InSitu Biologics’ unique technology should yield novel and effective treatment solutions for cancer patients. We look forward to having the Mayo team join us on this important journey to advance and improve therapeutic options in the cancer field,” said Mark Ereth, chief medical officer of InSitu Biologics.
Mayo Foundation for Medical Education and Research is a non-profit based in Rochester, Minnesota, with a mission of “inspiring hope and promoting health through integrated clinical practice, education and research.” Mayo now holds a financial interest in InSitu Biologics and its platform technology.
About InSitu Biologics
InSitu Biologics, Inc. is an emerging biotech company focused on the development of a multi-phase prolonged-release drug delivery platform for localized treatment of pain, cancer, and infection. The company is initially applying its disruptive technology to the unmet needs in the pain management and cancer therapy markets.
InSitu Biologics is currently conducting investigational pre-clinical work. It has no products approved for sale in any geography.
Partnering 2030: Biopharma Report
